Baird analyst Michael Ha said the weakness in Oscar Health (OSCR) following ts results is a buying opportunity and he expects the shares to trade back to around $18 in the near-term. Baird reiterated its Outperform rating and $28 price target on Oscar Health shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR: